drug

Tocilizumab

MeSH C502936
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Brian Miller
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Tocilizumab in Schizophrenia
NCT02874573Phase 1Unknown
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
NCT02034474Phase 4Completed
An Open-Label Trial of Tocilizumab in Schizophrenia
NCT01696929Phase 1Completed

KOLs & investigators

2
Brian Miller, MD, PhD, MPH
Ragy R Girgis, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Brian Miller
company
trial
Tocilizumab in Schizophrenia
PHASE1
trial
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
PHASE4
trial
An Open-Label Trial of Tocilizumab in Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Inflammation
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Brian Miller, MD, PhD, MPH
KOL score —
person
Ragy R Girgis, MD
KOL score —
person